Passa al contenuto
Merck
  • Enzymatic glycosylation of vancomycin aglycon: completion of a total synthesis of vancomycin and N- and C-terminus substituent effects of the aglycon substrate.

Enzymatic glycosylation of vancomycin aglycon: completion of a total synthesis of vancomycin and N- and C-terminus substituent effects of the aglycon substrate.

Organic letters (2014-06-24)
Atsushi Nakayama, Akinori Okano, Yiqing Feng, James C Collins, Karen C Collins, Christopher T Walsh, Dale L Boger
ABSTRACT

Studies on the further development of the sequential glycosylations of the vancomycin aglycon catalyzed by the glycosyltransferases GtfE and GtfD and the observation of unusual, perhaps unexpected, aglycon substrate substituent effects on the rate and efficiency of the initial glycosylation reaction are reported.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Vancomicina, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
Vancomicina, ≥85% (Vancomycin B)
Sigma-Aldrich
Vancomicina, BioReagent, suitable for plant cell culture
Sigma-Aldrich
Vancomicina, meets USP testing specifications
Sigma-Aldrich
Phosphorylase b from rabbit muscle, lyophilized powder, ≥20 units/mg protein, 2× crystallization
Millipore
Vancomycin supplement, suitable for microbiology
Vancomycin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Phosphorylase b from rabbit muscle, For use as a marker in SDS-PAGE